With the emergence of blockbuster drugs, such as Gazyva® (for Chronic Lymphocytic Leukemia) and POTELEGIO® (for Sézary syndrome), Fc engineered antibodies have garnered significant interest in the medical community, for various clinical conditions
London
Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market2021-2030” report to its list of offerings.
Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment the various immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule
To order this 250+ page report, which features 100+ figures and 110+ tables, please visit https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
Key Market Insights
The Fc engineered antibodies pipeline features more than 125 marketed drugs / drug development programs
Around 15% Fc protein and glyco-engineered antibodies are marketed, while close to 75% are being evaluated in different phases of clinical trials and 10% in preclinical studies. Examples of marketed Fc engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.
Around 30 companies claim to be engaged in the development of Fc protein and glyco-engineered antibodies
Around 55% of the aforementioned players are large companies (with more than 5000 employees). It is worth highlighting that, majority of the developers engaged in this domain (54%) are based in North America, followed by Europe (26%) and Asia-Pacific (20%).
Over 1,800 clinical trials are currently evaluating the therapeutic effects of Fc protein and glyco-engineered antibodies, worldwide
It is worth mentioning that most of the trials were / are being conducted in North America (35%) region;
however, more than 91% of the patients enrolled in trials conducted in North America were enrolled in different sites in the United States. Further, 43% of the trials are being sponsored by non-industry players.
To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market/request-sample.html
Key Questions Answered
- Who are the leading industry and non-industry players engaged in the development of Fc protein and glyco-engineered antibodies?
- Which are the key disease indications being targeted by Fc engineered antibodies?
- Which partnership models are commonly adopted by stakeholders engaged in this domain?
- Which geographies are the most active in conducting clinical trials on Fc protein and glyco-engineered antibodies?
- Which are the leading administering institutes supporting the research related to Fc protein and glyco-engineered antibodies?
- How has the intellectual property landscape in this market evolved over the years?
- Which key factors are likely to influence the evolution of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
For additional details, please visit
https://www.rootsanalysis.com/reports/fc-protein-engineered-and-glycoengineered-antibodies-market.html
or email sales@rootsanalysis.com
You may also be interested in the following titles:
- TIL-based Therapies Market, 2021-2030
- TCR-based Therapies Market, 2021-2030
Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com
Facebook – https://www.facebook.com/RootsAnalysis
LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter – https://twitter.com/RootsAnalysis
Medium – https://medium.com/@RootsAnalysis
Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/
Quora – https://rootsanalysisinsights.quora.com/
